Vol 9-2 Mini Review
Chimeric Antigen receptor-T cell Therapy for Solid Tumors with Antigen Heterogeneity.
Chimeric antigen receptor-T (CAR-T) cell therapy in the treatment of solid tumors remains limited, though it has demonstrated remarkable success for hematological malignancies. One of the major restrictions is immune escape from the attack mediated by primary targeted CAR-T cells, driven by the heterogeneous cell components of solid tumors, including heterogeneous expression of tumor antigens. Here, we reviewed the specified challenges and corresponding strategies which are being developed, including the use of multi-targeted CAR-T cells and the activation of endogenous immune responses.
DOI: 10.29245/2578-3009/2025/2.1261 View / Download Pdf